C4 Therapeutics, Inc. short interest in 2026
In 2026, C4 Therapeutics, Inc.'s disclosed short interest ran from 7.61% of shares outstanding on 15 Jan 2026 to 32.67% on 15 Sep 2026, a change of +25.06 percentage points. The year's high was 32.67% on 15 Sep 2026 and its low 7.35% on 13 Feb 2026, averaging 19.05% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.68 days on 15 Sep 2026. Full history: C4 Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 7.61% (15 Jan 2026)
- End of year
- 32.67% (15 Sep 2026)
- Change
- +25.06 pp
- High
- 32.67% (15 Sep 2026)
- Low
- 7.35% (13 Feb 2026)
- Average
- 19.05%
- Highest days to cover
- 22.68 (15 Sep 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 7.61% | 5.79 | |
| 30 Jan 2026 | 7.44% | 3.84 | |
| 13 Feb 2026 | 7.35% | 8.19 | |
| 27 Feb 2026 | 8.79% | 3.40 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 13.97% | 3.74 | |
| 31 Mar 2026 | 16.67% | 8.42 | |
| 15 Apr 2026 | 21.71% | 5.05 | |
| 30 Apr 2026 | 21.73% | 10.88 | |
| 15 May 2026 | 19.22% | 5.81 | 10-Q filed, results (8-K) |
| 29 May 2026 | 19.58% | 9.43 | |
| 15 Jun 2026 | 20.12% | 9.52 | |
| 30 Jun 2026 | 22.61% | 5.25 | |
| 15 Jul 2026 | 21.54% | 6.65 | |
| 31 Jul 2026 | 24.73% | 11.12 | |
| 14 Aug 2026 | 27.68% | 13.93 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 30.41% | 16.74 | |
| 15 Sep 2026 | 32.67% | 22.68 |
See also: C4 Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.